BNTX stock prediction was not too far from the actual trading price of $136.45 in pre-Market at 09:00 AM EDT
On October 6, BioNTech ( NASDAQ:BNTX ) announced that it had partnered with the Australian State of Victoria to conduct research and develop possible mRNA-based vaccinations and treatments. In accordance with the terms of the Letter of Intent, the parties will establish a research and innovation hub in Melbourne to aid in the translation of scholarly work into clinical development.
The German company also intends to construct a BioNTainer facility in Melbourne for the end-to-end clinical-scale manufacture of potential mRNA-based medicines. “Our BioNTainers are intended to serve as fully automated production facilities for mRNA-based pharmaceuticals and product candidates.” ” Once mRNA candidates are authorized, our BioNTainers in Melbourne will enable an end-to-end production process, including fill and finish,” said Sierk Poetting, CEO of BioNTech.
In order to further grow its clinical-stage oncology portfolio, which currently includes 18 product candidates in 23 ongoing trials, BioNTech plans to strengthen its clinical development capabilities in Australia and include sites.
The company announced that it is now enrolling cancer patients in Australia for two phases 2 mRNA-based treatments, BNT111 and BNT113 and that it has ambitions to expand its clinical research, including BNT211, which combines a CAR-T cell therapy strategy with an mRNA vaccination.
How quickly are the earnings per share on BNTX stoc...
Click here to read the full article on PressReach.com .Subscribe to the PressReach RSS feeds:
- Featured News RSS feed
- Investing News RSS feed
- Daily Press Releases RSS feed
- Trading Tips RSS feed
- Investing Videos RSS feed
Follow PressReach on Twitter
Subscribe to us on Youtube
PressReach Disclaimer .